Research progress in production of lipstatin fermentation

被引：0
作者：
Li L. [1 ]
Yu Y. [1 ]
Hu Y. [2 ]
机构：
[1] Department of Pharmaceutical and Chemical Engineering, Southeast University Chengxian College, Nanjing
[2] College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing
来源：
Huagong Jinzhan/Chemical Industry and Engineering Progress | 2021年 / 40卷 / 04期
关键词：
Fermentation; Lipstatin; Metabolic engineering; Streptomyces toxytricini;
D O I：
10.16085/j.issn.1000-6613.2020-1653
中图分类号：
学科分类号：
摘要：
Lipstatin is a β-lactone molecule which controls the digestive activity of pancreatic lipases and thus controls the absorption of fat in the small intestine. Lipstatin is supposed to inhibit the catalytic activity of pancreatic lipase by acylation of the serine residue present in the active site. A binding study suggests that one molecule of lipstatin binds with one molecule of lipase. Lipstatin is a natural product produced from Streptomyces toxytricini. The chemical structure is introduced,and the current application situation is reviewed. The progress in production of lipstatin fermentation is presented with a discussion on existing problems. Technology of metabolic engineering used in fermentation is introduced especially.The mechanism of lipstatin biosynthesis in bacteria is not yet clear, however acyl-coenzyme A carboxylase (ACCase) complex is playing key role in lipstatin biosynthesis. Furthermore, prospect for future research is proposed. © 2021, Chemical Industry Press Co., Ltd. All right reserved.
引用
收藏
页码：2251 / 2257
页数：6
相关论文
共 48 条
  • [1] HOCHULI E, KUPFER E, MAURER R, Et al., Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytriciniⅡ.Chemistry and structure elucidation, J. Antibiot, 40, 8, pp. 1086-1091, (1987)
  • [2] WEIBEL E K, HADVARY P, HOCHULI E., Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. Ⅰ. Producing organism, fermentation, isolation and biological activity, Antibiot, 40, 8, pp. 1081-1085, (1987)
  • [3] CARTER R, MOURALIDARANE A, RAY S, Et al., Recent advancements in drug treatment of obesity, Clin. Med, 12, 5, pp. 456-460, (2012)
  • [4] MELIA A T, ZHI J, ZELASKO R, Et al., The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers, Eur. J. Clin. Pharmacol, 54, 9, pp. 773-775, (1998)
  • [5] AHN SM, KIM H, JI E, Et al., The effect of orlistat on weight reduction in obese and overweight Korean patients, Arch. Pharm. Res, 37, 4, pp. 512-519, (2014)
  • [6] NG M, FLEMING T, ROBINSON M, Et al., Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013, Lancet, 384, 9945, pp. 766-784, (2016)
  • [7] DAVIDSON M H, HAUPTMAN J, DIGIROLAMO M, Et al., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat, The Journal of the American Medical Association, 281, 3, pp. 235-243, (1999)
  • [8] LIU T T, LIU X T, CHEN Q X, Et al., Lipase inhibitors for obesity: a review, Biomed. Pharmacother, 108, (2020)
  • [9] KUMAR P, DUBEY K K., Current trends and future prospects of lipstatin: a lipase inhibitor and pro-drug for obesity, RSC Adv, 5, pp. 86954-86966, (2015)
  • [10] CHAKRAVARTY B, GU Z, CHIRALA S S, Et al., Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain, Proc. Natl. Acad. Sci. USA, 101, 44, pp. 15567-15572, (2004)
12345